During the recent session, Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s traded shares were 0.51 million, with the beta value of the company hitting 0.29. At the last check today, the stock’s price was $3.94, reflecting an intraday loss of -21.10% or -$1.06. The 52-week high for the KPTI share is $16.95, that puts it down -330.2 from that peak though still a striking 10.91% gain since the share price plummeted to a 52-week low of $3.51. The company’s market capitalization is $34.08M, and the average intraday trading volume over the past 10 days was 69160.0 shares, and the average trade volume was 77.50K shares over the past three months.
Karyopharm Therapeutics Inc (KPTI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.80. KPTI has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
Karyopharm Therapeutics Inc (KPTI) registered a -21.10% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -21.10% in intraday trading to $3.94, hitting a weekly high. The stock’s 5-day price performance is -10.14%, and it has moved by -10.95% in 30 days. Based on these gigs, the overall price performance for the year is -61.11%. The short interest in Karyopharm Therapeutics Inc (NASDAQ:KPTI) is 2.02 million shares and it means that shorts have 23.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 21.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $14 respectively. As a result, KPTI is trading at a discount of -255.33% off the target high and 23.86% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 27.91%. While earnings are projected to return 15.48% in 2025, the next five years will return 47.98% per annum.
KPTI Dividends
Karyopharm Therapeutics Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders
Karyopharm Therapeutics Inc insiders own 6.39% of total outstanding shares while institutional holders control 42.62%, with the float percentage being 45.53%. VANGUARD GROUP INC is the largest shareholder of the company, while 68.0 institutions own stock in it. As of 2024-06-30, the company held over 7.65 million shares (or 6.3246% of all shares), a total value of $6.64 million in shares.
The next largest institutional holding, with 5.1 million shares, is of PALO ALTO INVESTORS LP’s that is approximately 4.2157% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.43 million.
Also, the Mutual Funds coming in first place with the largest holdings of Karyopharm Therapeutics Inc (KPTI) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 228.1 shares. This amounts to just over 2.64 percent of the company’s overall shares, with a $0.9 million market value. The same data shows that the other fund manager holds slightly less at 133.88, or about 1.55% of the stock, which is worth about $0.53 million.
